Paratek goes 3-for-3 in PhIII, but antibiotic stumbles on side effect profile
Paratek’s antibiotic omadacycline has now gone three for three in Phase III — setting up a pitch to the FDA — but the data on an oral …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
